Pre-made Farletuzumab benchmark antibody ( Whole mAb, anti-FOLR1 therapeutic antibody, Anti-FBP/FOLR/FRalpha/NCFTD Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-205

Pre-Made Farletuzumab biosimilar, Whole mAb, Anti-FOLR1 Antibody: Anti-FBP/FOLR/FRalpha/NCFTD therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Farletuzumab (MORAb-003) is a humanized monoclonal antibody[1] of IgG1/κ which is being investigated for the treatment of ovarian cancer.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-205-1mg 1mg 3090 Inquiry Inquiry

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Farletuzumab biosimilar, Whole mAb, Anti-FOLR1 Antibody: Anti-FBP/FOLR/FRalpha/NCFTD therapeutic antibody
INN Name Farletuzumab
TargetFOLR1
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2008
Year Recommended2009
CompaniesLudwig Institute for Cancer Research;Morphotek;Eisai Co Ltd
Conditions Approvedna
Conditions ActiveOvarian cancer;Non-small cell lung cancer
Conditions DiscontinuedSolid tumours
Development Techna